Plunkett Research Online: Antisense Therapeutics Limited

ANTISENSE THERAPEUTICS LIMITED (ATHJY:GREY) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Antisense Therapeutics Limited is a biopharmaceutical drug discovery and development company. The company has four products including ATL1102 injection for Multiple Scherosis, ATL1103 injection for growth & sight disorders, ATL1101 injection for prostate cancer, and ATL1102 inhaled for asthma......

Antisense Therapeutics Limited
Ticker: ATHJY
Exchange: GREY
Parent Company:
Year Established:
Fiscal Year Ends in

Phone: 61 398278999
Fax: 61 398271166
Address: 6-8 Wallace Avenue
Melbourne, VIC 3142 Australia

Types Of Business
Industry Ranks

Industry NAICS code:

Research and Development in Biotechnology
Pharmaceutical Preparation Manufacturing
Contacts Description

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2019 2018 2017 2016 2015 2014
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: